首页> 外文OA文献 >AB0426 COMPARISON OF INFLUENCES OF DIFFERENT CONCOMITANT DRUGS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH IGURATIMOD, A CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUG DEVELOPED IN JAPAN, IN REAL-WORLD CLINICAL SETTING

【2h】

AB0426 COMPARISON OF INFLUENCES OF DIFFERENT CONCOMITANT DRUGS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH IGURATIMOD, A CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUG DEVELOPED IN JAPAN, IN REAL-WORLD CLINICAL SETTING

机译：AB0426在现实世界临床环境中，在Iguratimod治疗IGURATIMOD治疗的类风湿性关节炎患者中不同伴随药物对类风湿性关节炎患者的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yuji Hirano; Daisuke Kihira; Yukiyoshi Oishi;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI) [J] . Doerner T., Schulze-Koops H., Burmester G. -R., Clinical and experimental rheumatology . 2019,第6期

机译：类风湿性关节炎患者的早期和晚期反应是常规的合成疾病改性抗风湿药物不足的响应者，并用TOCOLIZUAB处理或切换到Rituximab：开放标签第3阶段试验（MIRAI）
2. The Finnish Early Rheumatoid Arthritis Study (FIN-ERA) reveals major differences in the use of conventional synthetic disease-modifying anti-rheumatic drugs (cs-DMARDs) in patients with early rheumatoid arthritis (RA) [J] . Rannio T., Asikainen J., Hannonen P., Scandinavian journal of rheumatology . 2015,第6期

机译：芬兰早期类风湿关节炎研究（FIN-ERA）揭示了在早期类风湿关节炎（RA）患者中使用传统的可改变疾病综合性抗风湿药（cs-DMARDs）的主要差异
3. Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-kappa B and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients [J] . Ishikawa Koichiro, Ishikawa Junichiro Modern rheumatology . 2019,第3期

机译：Iguratimod，一种抑制抗风湿药物的合成疾病，抑制NF-κB的激活和RANKL的产生：其疗效，放射线摄影，安全性和预测因子对日本类风湿性关节炎患者的治疗多年来
4. Original article: Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting [O] . Huifang Liang, Raghava Danwada, Dianlin Guo, 2019

机译：原始文章：类风湿关节炎患者的住院静脉血栓栓塞发生率以及与在现实环境中转换生物制剂或靶向合成疾病修饰抗风湿药（DMARDs）的关联
5. Effects of an Anti-RANKL Antibody Denosumab on Joint Structural Damage in Patients with Rheumatoid Arthritis Treated with Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DESIRABLE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial [O] . Tsutomu Takeuchi, Yoshiya Tanaka, Satoshi Soen, 2018

机译：抗RANKL抗体Denosumab对用常规合成疾病改性抗风湿药物治疗类风湿性关节炎患者联合结构损伤的影响（理想的研究）：随机，双盲，安慰剂控制第3期试验

AB0426 COMPARISON OF INFLUENCES OF DIFFERENT CONCOMITANT DRUGS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH IGURATIMOD, A CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUG DEVELOPED IN JAPAN, IN REAL-WORLD CLINICAL SETTING

著录项

引文网络

相似文献

相关主题

期刊订阅